Contineum Therapeutics, Inc. (NASDAQ:CTNM – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $16.44 and last traded at $16.4250, with a volume of 360253 shares. The stock had previously closed at $15.00.
Analyst Ratings Changes
A number of research firms recently weighed in on CTNM. Wall Street Zen raised Contineum Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Morgan Stanley increased their price target on Contineum Therapeutics from $14.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Monday, April 20th. Finally, Robert W. Baird lifted their target price on shares of Contineum Therapeutics from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Friday, March 6th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $20.00.
View Our Latest Research Report on Contineum Therapeutics
Contineum Therapeutics Stock Performance
Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.16. Sell-side analysts predict that Contineum Therapeutics, Inc. will post -1.68 EPS for the current fiscal year.
Institutional Investors Weigh In On Contineum Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada lifted its holdings in shares of Contineum Therapeutics by 73.5% in the first quarter. Royal Bank of Canada now owns 5,794 shares of the company’s stock worth $76,000 after acquiring an additional 2,454 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Contineum Therapeutics by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 213,869 shares of the company’s stock worth $2,446,000 after buying an additional 2,819 shares during the last quarter. Eversept Partners LP lifted its stake in shares of Contineum Therapeutics by 2.1% in the 4th quarter. Eversept Partners LP now owns 137,493 shares of the company’s stock valued at $1,572,000 after acquiring an additional 2,874 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Contineum Therapeutics during the fourth quarter valued at about $43,000. Finally, Strs Ohio bought a new position in Contineum Therapeutics during the first quarter worth $27,000.
About Contineum Therapeutics
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.
Read More
- Five stocks we like better than Contineum Therapeutics
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
